We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 17, 2020

Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC

The New England Journal of Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
N. Engl. J. Med 2020 Sep 03;383(10)944-957, J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, T Hida, M de Jonge, SV Orlov, EF Smit, PJ Souquet, J Vansteenkiste, M Hochmair, E Felip, M Nishio, M Thomas, K Ohashi, R Toyozawa, TR Overbeck, F de Marinis, TM Kim, E Laack, A Robeva, S Le Mouhaer, M Waldron-Lynch, B Sankaran, OA Balbin, X Cui, M Giovannini, M Akimov, RS Heist

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading